--- title: "Liberate Bio gains licences for myeloid-specific CAR design patents" type: "News" locale: "en" url: "https://longbridge.com/en/news/278075152.md" description: "Liberate Bio has secured exclusive and non-exclusive licenses for patents on CAR designs specific to myeloid cells, enhancing its in vivo CAR-M therapies. The licenses, obtained from Carisma Therapeutics and the University of Pennsylvania, include engineered methods for monocytes and macrophages. The company aims to advance its CAR-M candidate into clinical trials by late 2026, leveraging its lipid nanoparticle technology for targeted immune cell programming." datetime: "2026-03-06T10:11:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278075152.md) - [en](https://longbridge.com/en/news/278075152.md) - [zh-HK](https://longbridge.com/zh-HK/news/278075152.md) --- # Liberate Bio gains licences for myeloid-specific CAR design patents With optimised CAR-sequence intellectual property and cell-selective LNP technology, Liberate Bio can advance in vivo CAR-M therapies. Credit: sirtravelalot / Shutterstock.com. Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for myeloid cells, such as monocytes and macrophages. The licences sourced from Carisma Therapeutics and the University of Pennsylvania include methods and constructs specifically engineered for function within these immune cell populations. ### Go deeper with GlobalData - ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png) Reports #### LOA and PTSR Model - Idecabtagene Vicleucel in Multiple Myeloma (Ka... - ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png) Reports #### LOA and PTSR Model - Lisocabtagene Maraleucel in Chronic Lymphocyti... ##### Go deeper with GlobalData The gold standard of business intelligence. Find out more #### Discover B2B Marketing That Performs Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms. Find out more The designs complement Liberate Bio’s lipid nanoparticle (LNP) delivery platform, which enables the selective programming of macrophages and monocytes in vivo. With both the optimised CAR-sequence intellectual property and its cell-selective LNP technology, Liberate Bio is now positioned to advance in vivo CAR-M therapies into clinical assessment. Liberate Bio’s Raptor platform conducts direct screening of LNPs in non-human primates to discover delivery vehicles aimed at extrahepatic immune cells. The company has previously disclosed that its lead LNP resulted in more than 99% depletion of circulating B cells in non-human primates by selectively programming monocytes and macrophages. GlobalData Strategic Intelligence # US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Liberate Bio’s chief scientific officer Walter Strapps said: “This licensing agreement meaningfully strengthens our clinical programmes. Myeloid cells have unique biology distinct from T cells, and CAR constructs optimised for their activation and persistence are essential. “By combining validated methods for CAR designs with our myeloid-selective LNP platform, we are building a differentiated and highly integrated approach to in vivo cell therapy.” Liberate Bio CEO Shawn Davis said: “In vivo CAR-M represents a new chapter in immune reprogramming. By uniting best-in-class delivery with optimised myeloid CAR designs, we are establishing a durable foundation for a scalable and potentially safer alternative to CAR-T — one capable of reaching broader patient populations across autoimmune and oncology indications.” The company intends to progress its initial in vivo CAR-M candidate into investigational new drug (IND)-enabling studies, targeting initial clinical evaluation via an investigator-initiated trial in the latter half of 2026. ### Related Stocks - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [CARM.US](https://longbridge.com/en/quote/CARM.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [Mesoblast Secures Exclusive CAR-MSC Technology License; Stock Up](https://longbridge.com/en/news/282790104.md) - [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md) - [Sana Announces Strategic Collaboration With Mayo Clinic For Developing Type-1 Diabetes Therapy SC451](https://longbridge.com/en/news/282645188.md) - [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md) - [ZAWYA: CE-Ventures announces acquisition of portfolio company CrossBridge Bio by Eli Lilly](https://longbridge.com/en/news/282695762.md)